Top

21-06-2015 | Vasculitis | Review | Article

Epigenetics and Vasculitis: a Comprehensive Review

Journal: Clinical Reviews in Allergy & Immunology

Authors: Paul Renauer, Patrick Coit, Amr H. Sawalha

Abstract

Vasculitides represent a group of relatively rare systemic inflammatory diseases of the blood vessels. Despite recent progress in understanding the genetic basis and the underlying pathogenic mechanisms in vasculitis, the etiology and pathogenesis of vasculitis remain incompletely understood. Epigenetic dysregulation plays an important role in immune-mediated diseases, and the contribution of epigenetic aberrancies in vasculitis is increasingly being recognized. Histone modifications in the PR3 and MPO gene loci might be mechanistically involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Similarly, other studies revealed important epigenetic contribution to other vasculitides, including Kawasaki disease and IgA vasculitis. More recently, genome-wide epigenomic studies have been performed in several vasculitides. A recent genome-wide DNA methylation study uncovered an important role for epigenetic remodeling of cytoskeleton-related genes in the pathogenesis of Behçet’s disease and suggested that reversal of some of these DNA methylation changes associates with disease remission. Genome-wide DNA methylation profiling characterized the inflammatory response in temporal artery tissue from patients with giant cell arteritis and showed increased activation of calcineurin/nuclear factor of activated T cells (NFAT) signaling, prompting the suggestion that a specific calcineurin/NFAT inhibitor that is well tolerated and with the added beneficial anti-platelet activity, such as dipyridamole, might be of therapeutic potential in giant cell arteritis. While epigenetic studies in systemic vasculitis are still in their infancy, currently available data clearly indicate that investigating the epigenetic mechanisms underlying these diseases will help to better understand the pathogenesis of vasculitis and provide novel targets for the development of disease biomarkers and new therapies.

Jennette JC et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11CrossRefPubMed

Hoffman GS, Calabrese LH (2014) Vasculitis: determinants of disease patterns. Nat Rev Rheumatol 10(8):454–62CrossRefPubMed

Carmona FD, Martin J, Gonzalez-Gay MA (2015) Genetics of vasculitis. Curr Opin Rheumatol 27(1):10–7CrossRefPubMed

Miller FW et al (2012) Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun 39(4):259–71CrossRefPubMedPubMedCentral

Selmi C et al (2012) Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun 39(4):272–84CrossRefPubMed

Stratta P et al (2001) The role of metals in autoimmune vasculitis: epidemiological and pathogenic study. Sci Total Environ 270(1–3):179–90CrossRefPubMed

Lane SE et al (2003) Are environmental factors important in primary systemic vasculitis? A case–control study. Arthritis Rheum 48(3):814–23CrossRefPubMed

Hogan SL et al (2007) Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case–control study. Clin J Am Soc Nephrol 2(2):290–9CrossRefPubMedPubMedCentral

Cartin-Ceba R, Peikert T, Specks U (2012) Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep 14(6):481–93CrossRefPubMed

10.

Lidar M et al (2012) Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia. Clin Rev Allergy Immunol 42(2):238–46CrossRefPubMed

11.

Chimenti MS et al (2014) Vasculitides and the complement system: a comprehensive review. Clin Rev Allergy Immunol

12.

Konstantinov KN, Ulff-Moller CJ, Tzamaloukas AH (2015) Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms. Autoimmun Rev 14(3):201–3CrossRefPubMed

13.

Wolffe AP, Matzke MA (1999) Epigenetics: regulation through repression. Science 286(5439):481–6CrossRefPubMed

14.

Lu Q (2013) The critical importance of epigenetics in autoimmunity. J Autoimmun 41:1–5CrossRefPubMed

15.

Lister R et al (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271):315–22CrossRefPubMedPubMedCentral

16.

Renauer PA, Coit P, Sawalha AH (2015) The DNA methylation signature of human TCRalphabeta+CD4-CD8- double negative T cells reveals CG demethylation and a unique epigenetic architecture permissive to a broad stimulatory immune response. Clin Immunol 156(1):19–27CrossRefPubMedPubMedCentral

17.

Balada E, Ordi-Ros J, Vilardell-Tarres M (2007) DNA methylation and systemic lupus erythematosus. Ann N Y Acad Sci 1108:127–36CrossRefPubMed

18.

Deaton AM, Bird A (2011) CpG islands and the regulation of transcription. Genes Dev 25(10):1010–22CrossRefPubMedPubMedCentral

19.

Bird AP, Wolffe AP (1999) Methylation-induced repression—belts, braces, and chromatin. Cell 99(5):451–4CrossRefPubMed

20.

Surani MA (1998) Imprinting and the initiation of gene silencing in the germ line. Cell 93(3):309–12CrossRefPubMed

21.

Zhang Y et al (2013) Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun 41:92–9CrossRefPubMed

22.

Gupta B, Hawkins RD (2015) Epigenomics of autoimmune diseases. Immunol Cell Biol 93(3):271–6CrossRefPubMed

23.

Bhaumik SR, Smith E, Shilatifard A (2007) Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14(11):1008–16CrossRefPubMed

24.

Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693–705CrossRefPubMed

25.

Lee GR et al (2006) T helper cell differentiation: regulation by cis elements and epigenetics. Immunity 24(4):369–79CrossRefPubMed

26.

Liu Y et al (2013) Epigenetics in immune-mediated pulmonary diseases. Clin Rev Allergy Immunol 45(3):314–30CrossRefPubMed

27.

Deng X et al (2015) The role of microRNAs in autoimmune diseases with skin involvement. Scand J Immunol 81(3):153–65CrossRefPubMed

28.

Mello CC, Conte D Jr (2004) Revealing the world of RNA interference. Nature 431(7006):338–42CrossRefPubMed

29.

Fabian MR, Sonenberg N (2012) The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 19(6):586–93CrossRefPubMed

30.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–97CrossRefPubMed

31.

Singh RP et al (2013) The role of miRNA in inflammation and autoimmunity. Autoimmun Rev 12(12):1160–5CrossRefPubMed

32.

Zeng L et al (2014) The emerging role of circulating microRNAs as biomarkers in autoimmune diseases. Autoimmunity 47(7):419–29CrossRefPubMed

33.

Hilhorst M et al (2015) Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol

34.

Calafat J et al (1990) In situ localization by double-labeling immunoelectron microscopy of anti-neutrophil cytoplasmic autoantibodies in neutrophils and monocytes. Blood 75(1):242–50PubMed

35.

van der Woude FJ et al (1985) Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1(8426):425–9CrossRefPubMed

36.

Falk RJ, Jennette JC (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318(25):1651–7CrossRefPubMed

37.

Goeken JA (1991) Antineutrophil cytoplasmic antibody—a useful serological marker for vasculitis. J Clin Immunol 11(4):161–74CrossRefPubMed

38.

Cohen Tervaert JW, Damoiseaux J (2012) Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol 43(3):211–9CrossRefPubMed

39.

Tervaert JW et al (1990) Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 33(8):1264–72CrossRefPubMed

40.

Falk RJ et al (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 87(11):4115–9CrossRefPubMedPubMedCentral

41.

Little MA et al (2005) Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106(6):2050–8CrossRefPubMed

42.

Xiao H et al (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110(7):955–63CrossRefPubMedPubMedCentral

43.

Xiao H et al (2007) Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170(1):52–64CrossRefPubMedPubMedCentral

44.

Zeisberg M (2011) ANCA vasculitis meets epigenetics—closing in on the molecular roots of disease. Nephrol Dial Transplant 26(4):1146–8CrossRefPubMed

45.

Borregaard N, Cowland JB (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89(10):3503–21PubMed

46.

Cowland JB, Borregaard N (1999) The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukoc Biol 66(6):989–95PubMed

47.

Yang JJ et al (2004) Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol 15(8):2103–14CrossRefPubMed

48.

Ciavatta DJ et al (2010) Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 120(9):3209–19CrossRefPubMedPubMedCentral

49.

Luo S et al (2013) Aberrant histone modifications in peripheral blood mononuclear cells from patients with Henoch–Schonlein purpura. Clin Immunol 146(3):165–75CrossRefPubMed

50.

Kuo HC et al (2015) Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array. Arthritis Rheumatol 67(3):828–36CrossRefPubMed

51.

Ryu J et al (2007) FcgammaRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc Res 75(3):555–65CrossRefPubMed

52.

Hughes T et al (2014) Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behcet’s disease. Arthritis Rheumatol 66(6):1648–58CrossRefPubMedPubMedCentral

53.

Coit P et al (2015) DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-207116

54.

Audemard-Verger A et al (2015) IgA vasculitis (Henoch–Shonlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev 14(7):579–585CrossRefPubMed

55.

Ni FF et al (2014) Regulatory T cell microRNA expression changes in children with acute Kawasaki disease. Clin Exp Immunol 178(2):384–93CrossRefPubMedPubMedCentral

56.

Guo MM et al (2015) Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy 70(3):310–8CrossRefPubMed

57.

Shimizu C et al (2013) Differential expression of miR-145 in children with Kawasaki disease. PLoS One 8(3), e58159CrossRefPubMedPubMedCentral

58.

Yun KW et al (2014) Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease. Pediatr Cardiol 35(5):745–52CrossRefPubMed

59.

Magenta A et al (2011) miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 18(10):1628–39CrossRefPubMedPubMedCentral

60.

Li Y et al (2015) The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer. Oncotarget 6(11):9099–112CrossRefPubMedPubMedCentral

61.

Zhou Q et al (2012) Decreased microRNA-155 expression in ocular Behcet’s disease but not in Vogt Koyanagi Harada syndrome. Invest Ophthalmol Vis Sci 53(9):5665–74CrossRefPubMed

62.

Tang Y et al (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60(4):1065–75CrossRefPubMed

63.

Zhou Q et al (2014) MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet’s disease and Vogt–Koyanagi–Harada syndrome. Ann Rheum Dis 73(1):170–6CrossRefPubMed

64.

Qi J et al (2013) A functional variant of pre-miRNA-196a2 confers risk for Behcet’s disease but not for Vogt–Koyanagi–Harada syndrome or AAU in ankylosing spondylitis. Hum Genet 132(12):1395–404CrossRefPubMed

65.

Yu H et al (2014) Predisposition to Behcet’s disease and VKH syndrome by genetic variants of miR-182. J Mol Med (Berl) 92(9):961–7CrossRef

66.

Stittrich AB et al (2010) The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol 11(11):1057–62CrossRefPubMed

67.

Ambrose NL, Haskard DO (2013) Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol 9(2):79–89CrossRefPubMed

68.

Mat MC et al (2014) Behcet’s disease as a systemic disease. Clin Dermatol 32(3):435–42CrossRefPubMed

69.

Tulunay A et al (2015) Activation of the JAK/STAT pathway in Behcet’s disease. Genes Immun 16(2):170–5CrossRefPubMedPubMedCentral

70.

Hirohata S (2008) Histopathology of central nervous system lesions in Behcet’s disease. J Neurol Sci 267(1–2):41–7CrossRefPubMed

71.

Direskeneli H, Fujita H, Akdis CA (2011) Regulation of TH17 and regulatory T cells in patients with Behcet disease. J Allergy Clin Immunol 128(3):665–6CrossRefPubMed

72.

Geri G et al (2011) Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J Allergy Clin Immunol 128(3):655–64CrossRefPubMed

73.

Aktas Cetin E et al (2014) IL-22-secreting Th22 and IFN-gamma-secreting Th17 cells in Behcet’s disease. Mod Rheumatol 24(5):802–7CrossRefPubMed

74.

Ceppi M et al (2009) MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A 106(8):2735–40CrossRefPubMedPubMedCentral

75.

O’Connell RM et al (2010) MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33(4):607–19CrossRefPubMedPubMedCentral

76.

Hu R et al (2013) MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression. J Immunol 190(12):5972–80CrossRefPubMedPubMedCentral

77.

Yu Z et al (2007) Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 35(13):4535–41CrossRefPubMedPubMedCentral

78.

Paine A et al (2010) Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol 80(12):1895–903CrossRefPubMed

79.

Gonzalez-Gay MA et al (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61(10):1454–61CrossRefPubMed

80.

De Smit E, Palmer AJ, Hewitt AW (2015) Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol 42(1):119–25CrossRefPubMed

81.

Djuretic IM et al (2007) Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat Immunol 8(2):145–53CrossRefPubMed

82.

Grewal IS, Flavell RA (1996) The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153:85–106CrossRefPubMed

83.

Flanagan WM et al (1991) Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352(6338):803–7CrossRefPubMed

84.

Schaufelberger C et al (2006) No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 35(4):327–9CrossRefPubMed

85.

Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–508PubMed

86.

Balakumar P et al (2014) Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel? Pharmacol Res 87:144–50CrossRefPubMed

87.

Mulero MC et al (2009) Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity. J Biol Chem 284(14):9394–401CrossRefPubMedPubMedCentral

88.

Kyttaris VC et al (2011) Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum 63(7):2058–66CrossRefPubMedPubMedCentral

89.

Feil R, Fraga MF (2011) Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 13(2):97–109

90.

Weyand CM, Liao YJ, Goronzy JJ (2012) The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol 32(3):259–65CrossRefPubMedPubMedCentral

91.

Li Y et al (2010) Age-dependent decreases in DNA methyltransferase levels and low transmethylation micronutrient levels synergize to promote overexpression of genes implicated in autoimmunity and acute coronary syndromes. Exp Gerontol 45(4):312–22CrossRefPubMedPubMedCentral

Medicine Matters Rheumatology

Abstract